Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Gro...(DAYTRANA that was launched last year rep...)

The acquisition of New River Pharmaceuticals gave us full ownership and control of VYVANSE, and this new generation ADHD treatment is establishing itself in the US, where it has already gained a market share of 6%(i). The launch of VYVANSE continues to progress well and we are confident about the medication's future growth supported by new clinical studies and expected additional indications. Our total ADHD franchise has now grown to 32% of the total US ADHD market, compared to 28% at the end of 2006, extending our leadership position in this specialist area.

We've also acquired five pipeline compounds in new technologies and new markets, by licensing the marketing and co-development rights to a range of both biological and small molecule products from Renovo, Amicus Therapeutics and Alba Therapeutics.

Looking forward, we will continue to execute our strategy, which has provided good returns for shareholders, by building on the success of our growing specialist drugs portfolio focused on the treatment of symptomatic diseases. We currently expect 2008 revenue growth to be in the mid to high teens range and positive revenue growth through 2010."

(i) per IMS weekly prescription data at February 8, 2008

Product Highlights

- VYVANSE(TM) - Attention Deficit and Hyperactivity Disorder ("ADHD").

- Approved by the US Food and Drug Administration ("FDA") for use in the pediatric population in February 2007 and launched in the US in July 2007 (dosage strengths 30mg, 50mg and 70mg).

- On December 10, 2007 the FDA approved three additional dosage strengths (20mg, 40mg and 60mg) which will be available in retail pharmacies in the US in the second quarter of 2008. These additional strengths are designed to increase dosing flexibility.

- By February 15, 2008 VYVANSE had achieved a US ADHD market share of 6.3% based on daily presc
'/>"/>